Sp229

TRAINING THE NEXT GENERATION OF AI-ENABLED CLINICIANS: ESTABLISHING DIGITAL COMPETENCY

Date
May 18, 2024
Explore related products in the following collection:


Tracks

Related Products

Thumbnail for RNA SEQUENCING FROM BIOPSIES PERFORMED DURING FOOD ELIMINATION AND REINTRODUCTION IDENTIFIES SIGNATURES INVOLVED IN EARLY RECURRENCE OF EOE
RNA SEQUENCING FROM BIOPSIES PERFORMED DURING FOOD ELIMINATION AND REINTRODUCTION IDENTIFIES SIGNATURES INVOLVED IN EARLY RECURRENCE OF EOE
RATIONALE: RNA sequencing studies have previously identified impaired barrier function and the subsequent proinflammatory response as critical to the pathogenies of EoE. However, the investigation into disease initiation is often limited by the inability to capture the disease early…
Thumbnail for COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS BASED ON ANATOMICAL CLASSIFICATION
COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS BASED ON ANATOMICAL CLASSIFICATION
BACKGROUND: Siewert's topographic classification (SW) has been used for treatment plan of esophagogastric junction adenocarcinomas (EGJA). But recently, molecular classifications categorized EGJA with similar characteristics and prognosis…
Thumbnail for PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
Thumbnail for INVESTIGATING THE EFFICACY OF ALPELISIB AND PI3Kα-S6K DUAL INHIBITION IN LIN28B-DRIVEN COLORECTAL CANCER METASTASIS
INVESTIGATING THE EFFICACY OF ALPELISIB AND PI3Kα-S6K DUAL INHIBITION IN LIN28B-DRIVEN COLORECTAL CANCER METASTASIS
Colorectal cancer (CRC) shows a dramatic drop in the five-year survival rate from 90% for localized tumors to 14% for metastatic CRC (mCRC). Our lab has identified LIN28B, an RNA-binding protein overexpressed in 30% of CRCs, as an oncogene that promotes CRC metastasis…